Janux Therapeutics, Inc. - 10-Q Filing
Janux Therapeutics filed its quarterly report on Form 10-Q for the period ended March 31, 2026. The filing includes unaudited financial statements showing research and development expenses of $45.8 million and general and administrative expenses of $9.7 million during Q1 2026.
Tickers: $JANX